Sensei Biotherapeutics (NASDAQ:SNSE) Earns “Buy” Rating from HC Wainwright

Sensei Biotherapeutics (NASDAQ:SNSE)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $4.00 price target on the stock.

Sensei Biotherapeutics Stock Down 1.2 %

Shares of NASDAQ SNSE opened at $0.43 on Friday. Sensei Biotherapeutics has a 12 month low of $0.38 and a 12 month high of $1.94. The business’s 50 day moving average is $0.47 and its two-hundred day moving average is $0.49. The company has a market cap of $10.84 million, a P/E ratio of -0.36 and a beta of 0.16.

Institutional Investors Weigh In On Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. National Bank of Canada FI raised its stake in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 45,575 shares of the company’s stock after purchasing an additional 35,575 shares during the quarter. National Bank of Canada FI owned 0.18% of Sensei Biotherapeutics worth $27,000 as of its most recent filing with the Securities and Exchange Commission. 10.50% of the stock is owned by hedge funds and other institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.